MELBOURNE, Australia — November 26, 2025 — Leads & Copy — Neurizon Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) has appointed Justine Conway, Global Head of Business Development at Elanco Animal Health (NYSE: ELAN), as a Board Observer.
Conway will act as Elanco’s representative in Neurizon’s Board activities. The appointment highlights the strong relationship between Neurizon and Elanco, as well as Elanco’s ongoing partnership with Neurizon.
The appointment comes after an exclusive global license agreement for Monepantel, the active pharmaceutical ingredient in NUZ-001. The agreement, announced on July 2, 2025, marks a significant milestone for Neurizon, supports the company’s regulatory foundations, and provides access to critical animal safety and manufacturing data.
This data is essential for future clinical trials, potential regulatory approvals, and global market entry. Conway has more than two decades of experience in the animal health and healthcare industries. She joined Elanco in 2020 and has held senior roles at Macquarie Bank and Bank of America Merrill Lynch.
Conway’s experience includes work in the pharmaceutical and biotech sectors, with expertise in mergers and acquisitions and capital raisings. As a Board Observer, Conway will attend and participate in all Board and committee meetings but will not have voting rights.
The company anticipates that Conway’s industry expertise and strategic insight will support Neurizon as it advances NUZ-001 toward late-stage development and global commercialization, including entry into the HEALEY ALS Platform Trial this quarter.
Non-Executive Chairman Sergio Duchini said Conway’s appointment brings exceptional global expertise into Neurizon’s governance framework. Duchini said her expertise, combined with Elanco’s commitment to NUZ-001, will be invaluable as Neurizon moves toward late-stage development and prepares for entry into the HEALEY ALS Platform Trial.
Duchini welcomed Conway to the company on behalf of the Board and management, and noted they look forward to benefiting from her insight as they continue to advance toward regulatory submission and global commercialization.
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. The company is developing NUZ-001 for the treatment of ALS, the most common form of motor neurone disease. The company’s strategy involves accelerating access to effective ALS treatments while exploring the potential of NUZ-001 for broader neurodegenerative applications.
NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction. Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.
Neurizon® is a registered trademark of Neurizon Therapeutics Limited.
Contact:
Sergio Duchini, Non-Executive Chairman
Source: Neurizon Therapeutics Limited
